AstraZeneca PLC
AZN89.830USD
-0.460-0.51%
終値 12/12, 16:00（ET）15分遅れの株価
278.60B時価総額
29.63直近12ヶ月PER
詳細情報 AstraZeneca PLC 企業名
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
AstraZeneca PLCの企業情報
企業コードAZN
会社名AstraZeneca PLC
上場日Sep 21, 2007
最高経営責任者「CEO」Dunoyer (Marc)
従業員数94300
証券種類Depository Receipt
決算期末Sep 21
本社所在地1 Francis Crick Avenue
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号CB2 0AA
電話番号442073045000
ウェブサイトhttps://www.astrazeneca.com/
企業コードAZN
上場日Sep 21, 2007
最高経営責任者「CEO」Dunoyer (Marc)
AstraZeneca PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
他の
6.33B
45.89%
地域別USD
会社名
収益
比率
United States
6.32B
45.84%
Europe
3.07B
22.23%
EX-China
2.04B
14.82%
China
1.71B
12.40%
Established ROW
1.31B
9.53%
事業別
地域別
事業別USD
会社名
収益
比率
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
他の
6.33B
45.89%
株主
更新時刻: Tue, Nov 25
更新時刻: Tue, Nov 25
株主統計
種類
株主統計
株主統計
比率
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
他の
95.15%
株主統計
株主統計
比率
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
他の
95.15%
種類
株主統計
比率
Investment Advisor
8.78%
Investment Advisor/Hedge Fund
5.84%
Research Firm
1.11%
Hedge Fund
0.69%
Bank and Trust
0.19%
Pension Fund
0.06%
Venture Capital
0.03%
Family Office
0.02%
Family Office
0.02%
他の
83.27%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
2038
518.15M
17.29%
+1.97M
2025Q3
2089
516.24M
17.34%
-2.62M
2025Q2
2062
519.46M
17.59%
-9.37M
2025Q1
2054
529.82M
17.91%
-25.96M
2024Q4
2001
537.38M
17.35%
+13.04M
2024Q3
1925
524.26M
17.32%
+244.85K
2024Q2
1912
524.03M
17.41%
+1.94M
2024Q1
1863
521.64M
17.31%
-15.18M
2023Q4
1837
514.30M
17.42%
-5.99M
2023Q3
1809
522.19M
17.30%
+4.27M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
PRIMECAP Management Company
41.20M
1.33%
+538.61K
+1.32%
Jun 30, 2025
Wellington Management Company, LLP
34.34M
1.11%
-1.29M
-3.63%
Jun 30, 2025
T. Rowe Price International Ltd
30.71M
0.99%
+3.43M
+12.56%
Jun 30, 2025
Capital International Investors
31.40M
1.01%
+119.42K
+0.38%
Jun 30, 2025
Managed Account Advisors LLC
21.15M
0.68%
-1.37M
-6.07%
Jun 30, 2025
Fisher Investments
20.70M
0.67%
+530.52K
+2.63%
Jun 30, 2025
Fidelity Management & Research Company LLC
18.04M
0.58%
-944.35K
-4.97%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.24M
0.68%
-8.57M
-28.75%
Jun 30, 2025
Sanders Capital, LLC
14.53M
0.47%
-542.12K
-3.60%
Jun 30, 2025
Putnam Investment Management, L.L.C.
12.48M
0.4%
+184.41K
+1.50%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
銘柄名
比率
Amplify Weight Loss Drug & Treatment ETF
5.58%
VanEck Pharmaceutical ETF
4.97%
Invesco Nasdaq Biotechnology ETF
4.81%
ProShares Ultra Nasdaq Biotechnology
4.81%
Parnassus Value Select ETF
4.66%
Invesco QQQ Low Volatility ETF
4.19%
Roundhill GLP-1 & Weight Loss ETF
3.36%
Abacus FCF International Leaders ETF
3.28%
Global X Aging Population ETF
3.2%
Franklin Genomic Advancements ETF
3.05%
詳細を見る
Amplify Weight Loss Drug & Treatment ETF
比率5.58%
VanEck Pharmaceutical ETF
比率4.97%
Invesco Nasdaq Biotechnology ETF
比率4.81%
ProShares Ultra Nasdaq Biotechnology
比率4.81%
Parnassus Value Select ETF
比率4.66%
Invesco QQQ Low Volatility ETF
比率4.19%
Roundhill GLP-1 & Weight Loss ETF
比率3.36%
Abacus FCF International Leaders ETF
比率3.28%
Global X Aging Population ETF
比率3.2%
Franklin Genomic Advancements ETF
比率3.05%
配当金
過去5年間の配当金総支払額は
20.90B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Jul 29, 2025
AZN.NB Final Cash Dividend of gross USD 0.515 paid on Sep 08, 2025 going ex on Aug 08, 2025
Aug 08, 2025
Sep 08, 2025
Aug 08, 2025
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
詳細を見る
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
AstraZeneca PLCの上位5名の株主は誰ですか？
AstraZeneca PLCの上位5名の株主は以下のとおりです。
PRIMECAP Management Companyは41.20M株を保有しており、これは全体の1.33%に相当します。
Wellington Management Company, LLPは34.34M株を保有しており、これは全体の1.11%に相当します。
T. Rowe Price International Ltdは30.71M株を保有しており、これは全体の0.99%に相当します。
Capital International Investorsは31.40M株を保有しており、これは全体の1.01%に相当します。
Managed Account Advisors LLCは21.15M株を保有しており、これは全体の0.68%に相当します。
PRIMECAP Management Companyは41.20M株を保有しており、これは全体の1.33%に相当します。
Wellington Management Company, LLPは34.34M株を保有しており、これは全体の1.11%に相当します。
T. Rowe Price International Ltdは30.71M株を保有しており、これは全体の0.99%に相当します。
Capital International Investorsは31.40M株を保有しており、これは全体の1.01%に相当します。
Managed Account Advisors LLCは21.15M株を保有しており、これは全体の0.68%に相当します。
AstraZeneca PLCの株主タイプ上位3種は何ですか？
AstraZeneca PLCの株主タイプ上位3種は、
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
AstraZeneca PLC（AZN）の株式を保有している機関の数はいくつですか？
2025Q4時点で、AstraZeneca PLCの株式を保有している機関は2038社あり、保有株式の総市場価値は約518.15Mで、全体の17.29%を占めています。2025Q3と比較して、機関の持ち株は-0.05%増加しています。
AstraZeneca PLCの最大の収益源は何ですか？
FY2025Q2において、Farxiga部門がAstraZeneca PLCにとって最大の収益を生み出しており、その金額は2.15Bで、全収益の15.59%を占めています。
